PL3452071T3 - Chimeryczne neurotoksyny - Google Patents
Chimeryczne neurotoksynyInfo
- Publication number
- PL3452071T3 PL3452071T3 PL17724335T PL17724335T PL3452071T3 PL 3452071 T3 PL3452071 T3 PL 3452071T3 PL 17724335 T PL17724335 T PL 17724335T PL 17724335 T PL17724335 T PL 17724335T PL 3452071 T3 PL3452071 T3 PL 3452071T3
- Authority
- PL
- Poland
- Prior art keywords
- chimeric neurotoxins
- neurotoxins
- chimeric
- Prior art date
Links
- 239000002581 neurotoxin Substances 0.000 title 1
- 231100000618 neurotoxin Toxicity 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1607901.4A GB201607901D0 (en) | 2016-05-05 | 2016-05-05 | Chimeric neurotoxins |
| PCT/EP2017/060821 WO2017191315A1 (en) | 2016-05-05 | 2017-05-05 | Chimeric neurotoxins |
| EP17724335.9A EP3452071B1 (en) | 2016-05-05 | 2017-05-05 | Chimeric neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3452071T3 true PL3452071T3 (pl) | 2021-10-25 |
Family
ID=56297235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17724335T PL3452071T3 (pl) | 2016-05-05 | 2017-05-05 | Chimeryczne neurotoksyny |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11434265B2 (pl) |
| EP (4) | EP3889168A1 (pl) |
| JP (4) | JP7421862B2 (pl) |
| KR (2) | KR20240033165A (pl) |
| CN (2) | CN116333158A (pl) |
| AR (1) | AR108689A1 (pl) |
| AU (4) | AU2017260389B2 (pl) |
| BR (1) | BR112018072587A2 (pl) |
| CA (1) | CA3020640A1 (pl) |
| DK (1) | DK3452071T3 (pl) |
| EA (1) | EA201892386A1 (pl) |
| ES (1) | ES2866899T3 (pl) |
| GB (1) | GB201607901D0 (pl) |
| HU (1) | HUE054856T2 (pl) |
| IL (1) | IL262575B (pl) |
| MX (1) | MX389707B (pl) |
| PL (1) | PL3452071T3 (pl) |
| PT (1) | PT3452071T (pl) |
| SA (1) | SA518400335B1 (pl) |
| SG (1) | SG11201809064QA (pl) |
| TW (3) | TW202415674A (pl) |
| UA (1) | UA126563C2 (pl) |
| WO (1) | WO2017191315A1 (pl) |
| ZA (1) | ZA202502076B (pl) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3372239B1 (en) | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| CA2880897C (en) | 2012-11-21 | 2020-01-14 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| WO2016154534A1 (en) | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EA201892784A1 (ru) * | 2016-06-08 | 2019-05-31 | Пол Стенмарк | Сконструированные ботулинические нейротоксины |
| CN110072880B (zh) | 2016-08-24 | 2025-02-18 | 哈佛大学校长及研究员协会 | 工程化肉毒杆菌神经毒素 |
| US12098169B2 (en) | 2017-09-29 | 2024-09-24 | Children's Medical Center Corporation | Enterococcus faecium neurotoxin (BoNT/EN) and derivatives thereof |
| TWI810228B (zh) | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| SE542539C2 (en) * | 2018-02-26 | 2020-06-02 | Toxotech Ab | Chimeric botulinum neurotoxin heavy chain binding domain |
| US20210024747A1 (en) * | 2018-04-06 | 2021-01-28 | Dupont Polymers, Inc. | Additive manufacturing compositions |
| AU2019260757B2 (en) | 2018-04-27 | 2023-09-28 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| US20220016221A1 (en) | 2018-12-05 | 2022-01-20 | Ipsen Biopharm Limited | Treatment of symptoms of traumatic brain injury |
| EP3753568A1 (en) | 2019-06-21 | 2020-12-23 | Fastox Pharma SA | Composition modulating botulinum neurotoxin effect |
| GB201914034D0 (en) * | 2019-09-30 | 2019-11-13 | Ipsen Biopharm Ltd | Treatment of neurological disorders |
| GB202001353D0 (en) * | 2020-01-31 | 2020-03-18 | Ipsen Biopharm Ltd | Treatment of skin conditions |
| KR20220154738A (ko) | 2020-03-16 | 2022-11-22 | 입센 바이오팜 리미티드 | 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소 |
| GB202003813D0 (en) | 2020-03-16 | 2020-04-29 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202100566D0 (en) | 2021-01-15 | 2021-03-03 | Ipsen Biopharm Ltd | Treatment of brain damage |
| GB202104294D0 (en) * | 2021-03-26 | 2021-05-12 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an exogenous activation loop |
| US20250066755A1 (en) | 2021-03-30 | 2025-02-27 | Ipsen Biopharm Limited | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders |
| AU2022247196A1 (en) | 2021-03-30 | 2023-10-05 | Ipsen Biopharm Limited | Treatment of pain & inflammatory disorders |
| CA3231083A1 (en) | 2021-09-16 | 2023-03-23 | Nicolae GRIGORE | Modified bont/a for use in the treatment of cervical dystonia |
| KR20240067100A (ko) | 2021-09-23 | 2024-05-16 | 입센 바이오팜 리미티드 | 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a |
| GB202113602D0 (en) | 2021-09-23 | 2021-11-10 | Ipsen Biopharm Ltd | Treatment of a disorder affecting an eyelid muscle of a subject |
| US20260014237A1 (en) | 2021-11-22 | 2026-01-15 | Ipsen Biopharm Limited | Treatment of pain |
| GB202116795D0 (en) | 2021-11-22 | 2022-01-05 | Ipsen Biopharm Ltd | Treatment of visceral pain |
| GB202206348D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202206353D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of cervical dystonia |
| GB202206362D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206361D0 (en) | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| CN116270998A (zh) * | 2023-03-15 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | 基于双受体结合区rbd组装的多价生物毒素抗原疫苗及其制备方法与应用 |
| WO2025093845A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| WO2025093844A1 (en) | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
| GB202320108D0 (en) | 2023-12-28 | 2024-02-14 | Ipsen Biopharm Ltd | Biosensor |
| KR20250122877A (ko) * | 2024-02-07 | 2025-08-14 | 주식회사 알케미어 | 보툴리눔 독소 e형의 경쇄 변이체 |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2329232T3 (es) | 1993-06-10 | 2009-11-24 | Allergan, Inc. | Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente. |
| US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US20040126396A1 (en) | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Botulinum toxin treatment for strabismus |
| US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
| US5670484A (en) | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| US5714469A (en) | 1994-09-01 | 1998-02-03 | Smithkline Beecham Corporation | Method of treating sepsis |
| US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
| GB9818548D0 (en) | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US6545126B1 (en) * | 1999-03-18 | 2003-04-08 | Wisconsin Alumni Research Foundation | Chimeric toxins |
| US6767544B2 (en) | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
| US6358917B1 (en) | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6265379B1 (en) | 1999-10-13 | 2001-07-24 | Allergan Sales, Inc. | Method for treating otic disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6143306A (en) | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
| US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
| US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6299893B1 (en) | 2000-04-17 | 2001-10-09 | Marvin Schwartz | Method to reduce hair loss and stimulate hair regrowth |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
| US6903187B1 (en) | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
| US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
| US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
| US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
| US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
| MXPA05003936A (es) | 2002-10-15 | 2005-06-17 | Allergan Inc | Terapias y procedimientos odontologicos con toxina botulinica. |
| US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US6838434B2 (en) | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
| US7220422B2 (en) | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| US20040253274A1 (en) | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| US7465457B2 (en) * | 2005-04-14 | 2008-12-16 | Wisconsin Alumni Research Foundation | Method for preparing botulinum neurotoxin type A light chain |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| AU2009286973B2 (en) * | 2008-08-29 | 2014-06-12 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins with altered persistency |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| WO2010120766A1 (en) | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| AU2015261716B2 (en) * | 2010-05-20 | 2018-01-04 | Allergan, Inc. | Degradable clostridial toxins |
| JP6148979B2 (ja) * | 2010-05-20 | 2017-06-14 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 分解性クロストリジウム毒素 |
| US8853360B2 (en) | 2010-06-23 | 2014-10-07 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin C1 with selective substrate specificity |
| GB201108108D0 (en) * | 2011-05-16 | 2011-06-29 | Syntaxin Ltd | Therapeutic fusion proteins |
| EP3279335B1 (en) * | 2011-12-31 | 2021-03-10 | Allergan, Inc. | Highly sensitive cell-based assay to detect the presence of active botulinum neurotoxin serotype-a |
| EP3372239B1 (en) * | 2012-05-30 | 2020-11-11 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| CA2880897C (en) * | 2012-11-21 | 2020-01-14 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| US9216210B2 (en) * | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| PT3242884T (pt) * | 2015-01-09 | 2021-04-22 | Ipsen Bioinnovation Ltd | Neurotoxinas catiónicas |
| WO2016154534A1 (en) * | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Engineered botulinum neurotoxin |
| EA201890587A1 (ru) * | 2015-08-27 | 2018-09-28 | Президент Энд Феллоуз Оф Гарвард Колледж | Композиции и способы для лечения боли |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| EA201892784A1 (ru) * | 2016-06-08 | 2019-05-31 | Пол Стенмарк | Сконструированные ботулинические нейротоксины |
| HUE061429T2 (hu) * | 2016-07-08 | 2023-06-28 | Childrens Medical Center | Új botulinum neurotoxin és származékai |
| CN110072880B (zh) * | 2016-08-24 | 2025-02-18 | 哈佛大学校长及研究员协会 | 工程化肉毒杆菌神经毒素 |
| WO2018172264A1 (en) * | 2017-03-24 | 2018-09-27 | Merz Pharma Gmbh & Co. Kgaa | Improved use of botulinum neurotoxin in the treatment of sialorrhea |
| US10329543B2 (en) * | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| CA3089834A1 (en) * | 2018-01-30 | 2019-08-08 | Children's Medical Center Corporation | Production of botulinum neurotoxins using bacillus systems |
| AU2019260757B2 (en) * | 2018-04-27 | 2023-09-28 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
-
2016
- 2016-05-05 GB GBGB1607901.4A patent/GB201607901D0/en not_active Ceased
-
2017
- 2017-05-05 BR BR112018072587-0A patent/BR112018072587A2/pt unknown
- 2017-05-05 ES ES17724335T patent/ES2866899T3/es active Active
- 2017-05-05 UA UAA201812004A patent/UA126563C2/uk unknown
- 2017-05-05 US US16/094,254 patent/US11434265B2/en active Active
- 2017-05-05 EP EP21161122.3A patent/EP3889168A1/en active Pending
- 2017-05-05 DK DK17724335.9T patent/DK3452071T3/da active
- 2017-05-05 KR KR1020247007005A patent/KR20240033165A/ko active Pending
- 2017-05-05 EP EP25226073.2A patent/EP4706669A2/en active Pending
- 2017-05-05 WO PCT/EP2017/060821 patent/WO2017191315A1/en not_active Ceased
- 2017-05-05 PT PT177243359T patent/PT3452071T/pt unknown
- 2017-05-05 TW TW113100764A patent/TW202415674A/zh unknown
- 2017-05-05 MX MX2018013141A patent/MX389707B/es unknown
- 2017-05-05 PL PL17724335T patent/PL3452071T3/pl unknown
- 2017-05-05 AU AU2017260389A patent/AU2017260389B2/en active Active
- 2017-05-05 KR KR1020187034781A patent/KR102643970B1/ko active Active
- 2017-05-05 TW TW106114984A patent/TWI751157B/zh active
- 2017-05-05 EP EP17724335.9A patent/EP3452071B1/en active Active
- 2017-05-05 TW TW111106023A patent/TWI832162B/zh active
- 2017-05-05 EA EA201892386A patent/EA201892386A1/ru unknown
- 2017-05-05 HU HUE17724335A patent/HUE054856T2/hu unknown
- 2017-05-05 EP EP25167599.7A patent/EP4603103A3/en active Pending
- 2017-05-05 AR ARP170101177A patent/AR108689A1/es unknown
- 2017-05-05 CA CA3020640A patent/CA3020640A1/en active Pending
- 2017-05-05 CN CN202210871196.6A patent/CN116333158A/zh active Pending
- 2017-05-05 JP JP2018558218A patent/JP7421862B2/ja active Active
- 2017-05-05 CN CN201780026413.9A patent/CN109069576B/zh active Active
- 2017-05-05 SG SG11201809064QA patent/SG11201809064QA/en unknown
-
2018
- 2018-10-24 IL IL262575A patent/IL262575B/en unknown
- 2018-10-29 SA SA518400335A patent/SA518400335B1/ar unknown
-
2021
- 2021-11-11 AU AU2021266312A patent/AU2021266312B2/en active Active
-
2022
- 2022-04-27 JP JP2022073033A patent/JP7682127B2/ja active Active
- 2022-07-12 US US17/811,958 patent/US12421284B2/en active Active
-
2023
- 2023-10-18 JP JP2023179513A patent/JP2024010008A/ja active Pending
-
2024
- 2024-04-10 AU AU2024202302A patent/AU2024202302B2/en active Active
- 2024-12-18 JP JP2024221406A patent/JP2025038136A/ja not_active Withdrawn
-
2025
- 2025-03-07 ZA ZA2025/02076A patent/ZA202502076B/en unknown
- 2025-12-16 AU AU2025283433A patent/AU2025283433A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262575B (en) | Chimeric neurotoxins | |
| ZA201704231B (en) | Chimeric protein | |
| DK3410992T3 (en) | Tilbagetrækkeligt udløb til stomipose | |
| AU201616677S (en) | Cylindres | |
| DK3770053T3 (en) | Batterilås til en elcykel | |
| GB201621111D0 (en) | Neurotoxins | |
| DK3343955T3 (en) | Anordning til et høreapparat | |
| GB201506223D0 (en) | Chimeric protein | |
| DK3270751T3 (en) | Foodprocessor | |
| GB201505306D0 (en) | Chimeric polypeptides | |
| AU201710564S (en) | Bookrack | |
| DK3481437T3 (en) | Precursorer til radiofluorering | |
| PL3458583T3 (pl) | Proteazy o polepszonej skuteczności | |
| GB201603320D0 (en) | Enhancing photosynthesis | |
| GB201513444D0 (en) | Peptoid | |
| DK3430280T3 (en) | Magnetisk leje til en turbomaskine | |
| DK3558418T3 (en) | Et infusionssystem til kortlivede radiofarmaceutika | |
| DK3430092T3 (en) | Coatingsystem | |
| AU201713059S (en) | SUNSHADE - square | |
| GB201418845D0 (en) | Improved sealing member | |
| HK40004434A (en) | Chimeric neurotoxins | |
| AU5499P (en) | T15-1218 Bituminaria bituminosa | |
| AU201713060S (en) | SUNSHADE - triangle | |
| GB201621467D0 (en) | Modified bulgeomers | |
| GB201612360D0 (en) | Improved shattaf |